Novartis AG
Methods for Treating EGFR Mutant Cancers
Last updated:
Abstract:
Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del), the acquired or resistant "gatekeeper" T790M mutation, or any combination of these mutations.
Status:
Application
Type:
Utility
Filling date:
1 Dec 2020
Issue date:
8 Apr 2021